LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Average Rating of “Moderate Buy” from Analysts

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) have earned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $8.50.

LFST has been the subject of a number of research reports. KeyCorp assumed coverage on LifeStance Health Group in a research report on Tuesday, April 8th. They issued an “overweight” rating and a $9.00 price objective for the company. UBS Group raised LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $8.50 target price for the company in a research report on Tuesday. William Blair reissued an “outperform” rating on shares of LifeStance Health Group in a report on Friday, February 28th. Finally, Canaccord Genuity Group initiated coverage on shares of LifeStance Health Group in a research note on Thursday, April 3rd. They issued a “buy” rating and a $8.00 price objective for the company.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, insider Lisa K. Miller sold 18,845 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.90, for a total value of $130,030.50. Following the transaction, the insider now directly owns 339,810 shares in the company, valued at $2,344,689. The trade was a 5.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in LifeStance Health Group by 1.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock worth $4,100,000 after acquiring an additional 11,331 shares during the last quarter. Voleon Capital Management LP acquired a new position in LifeStance Health Group in the first quarter worth $163,000. Petrus Trust Company LTA bought a new stake in shares of LifeStance Health Group during the first quarter worth $159,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of LifeStance Health Group by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock valued at $952,000 after buying an additional 4,169 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of LifeStance Health Group in the first quarter valued at about $7,932,000. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Stock Down 2.2%

NASDAQ LFST opened at $5.91 on Friday. LifeStance Health Group has a twelve month low of $4.64 and a twelve month high of $8.61. The stock has a market cap of $2.30 billion, a PE ratio of -22.73 and a beta of 1.30. The firm has a 50-day simple moving average of $6.34 and a 200 day simple moving average of $7.14. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.32 and a current ratio of 1.32.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.